CervoMed (CervoMed) Total Current Liabilities : $2.66 Mil (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is CervoMed Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. CervoMed's total current liabilities for the quarter that ended in Mar. 2024 was $2.66

CervoMed Total Current Liabilities Historical Data

The historical data trend for CervoMed's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CervoMed Total Current Liabilities Chart

CervoMed Annual Data

Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23

Total Current Liabilities

Get a 7-Day Free Trial 1.72 2.44 2.93 13.16 2.60

CervoMed Quarterly Data

Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24

Total Current Liabilities Get a 7-Day Free Trial 2.13 1.47 2.46 2.60 2.66

CervoMed Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

CervoMed's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 1.57 + 0

+ Other Current Liabilities + Current Deferred Liabilities

= 1.026 + 0

= 2.60

CervoMed's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 1.824 + 0

+ Other Current Liabilities + Current Deferred Liabilities

= 0.265 + 0.572

= 2.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

CervoMed Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of CervoMed's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CervoMed (CervoMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CervoMed Inc (NAS:CRVO) » Definitions » Total Current Liabilities

Comparable Companies

CRDF SGMT PRQR VXRT MDWD XFOR ADVM CNTX RIGL KOD OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX

Traded in Other Exchanges

N/A

Address

20 Park Plaza, Suite 424, Boston, MA, USA, 02216

Website

https://www.diffusionpharma.com

CervoMed Inc Formerly Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. Geographically business activity of the firm functions through the region of the United States.

Executives

Frank Zavrl director C/O PUMA BIOTECHNOLOGY INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024

Sylvie Gregoire director, 10 percent owner 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451

John William Tanner officer: Chief Financial Officer C/O EIP PHARMA, INC., 20 PARK PLAZA, SUITE 424, BOSTON MA 02116

Kelly Blackburn officer: VP, Clinical Development C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121

Marwan Sabbagh director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080

John J Alam director, 10 percent owner, officer: CEO and President 130 WAVERLY STREET, CAMBRIDGE MA 02139

Jeffrey V. Poulton director 300 THIRD STREET, CAMBRIDGE MA 02142

Jill Davidson director 300 EAST MAIN STREET, SUITE 101, CHARLOTTESVILLE VA 22902

Raven Jaeger officer: Chief Regulatory Officer 300 EAST MAIN STREET, SUITE 201, CHARLOTTESVILLE VA 22902

Eric Francois director C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713

Diana M Lanchoney director 1317 CARLTON AVE, SUITE 200, CHARLOTTESVILLE VA 22902

William Robert Elder officer: GC & Secretary 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902

Cobuzzi Robert Joseph Jr. director C/O DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902

Christopher D Galloway officer: Chief Medical Officer 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902

Jane H Hollingsworth director DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902

CervoMed (CervoMed) Headlines

From GuruFocus

Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer
By GuruFocusNews GuruFocusNews • 06-27-2022

Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
By GuruFocusNews GuruFocusNews • 06-21-2022

Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation
By PurpleRose PurpleRose • 07-26-2022

Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
By GuruFocusNews GuruFocusNews • 06-26-2022

Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC
By Value_Insider Value_Insider • 10-25-2022

Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci's History of Stockholder Value Destruction and Self-Dealing
By Value_Insider Value_Insider • 12-05-2022

Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
By GuruFocusNews GuruFocusNews • 07-01-2022

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies
By PRNewswire • 10-18-2023

Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
By Value_Insider Value_Insider • 11-14-2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FOCS, RADI, BGRY, DFFN
By PRNewswire PRNewswire • 05-23-2023

CervoMed Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Liabilities	Get a 7-Day Free Trial															2.13	1.47	2.46	2.60	2.66

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	1.57	+	0
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	1.026	+	0
	=	2.60

Frank Zavrl	director	C/O PUMA BIOTECHNOLOGY INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Sylvie Gregoire	director, 10 percent owner	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
John William Tanner	officer: Chief Financial Officer	C/O EIP PHARMA, INC., 20 PARK PLAZA, SUITE 424, BOSTON MA 02116
Kelly Blackburn	officer: VP, Clinical Development	C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Marwan Sabbagh	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
John J Alam	director, 10 percent owner, officer: CEO and President	130 WAVERLY STREET, CAMBRIDGE MA 02139
Jeffrey V. Poulton	director	300 THIRD STREET, CAMBRIDGE MA 02142
Jill Davidson	director	300 EAST MAIN STREET, SUITE 101, CHARLOTTESVILLE VA 22902
Raven Jaeger	officer: Chief Regulatory Officer	300 EAST MAIN STREET, SUITE 201, CHARLOTTESVILLE VA 22902
Eric Francois	director	C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713
Diana M Lanchoney	director	1317 CARLTON AVE, SUITE 200, CHARLOTTESVILLE VA 22902
William Robert Elder	officer: GC & Secretary	1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Cobuzzi Robert Joseph Jr.	director	C/O DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Christopher D Galloway	officer: Chief Medical Officer	1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Jane H Hollingsworth	director	DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902